LCM
IMGN

Lynx1 Capital Management’s Immunogen Inc IMGN Stock Holding History

Lynx1 Capital Management’s Portfolio IMGN Stock Details IMGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-1,543,259
Closed -$7.35M – 15
2022
Q1 		$7.35M Sell
1,543,259
-586,272
-28% -$3.25M 6.82% 7
2021
Q4 		$15.8M Buy
+2,129,531
New +$13.2M 13.79% 5

Other funds holding IMGN

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Lynx1 Capital Management's IMGN Position: Q2 2022 in Review

Lynx1 Capital Management sold out of Immunogen Inc (IMGN) in Q2 2022, closing a stake of 1,543,259 shares — an estimated $7.35M sold.

Lynx1 Capital Management first reported a position in IMGN in Q4 2021 and held it in 2 quarters. The position peaked at $15.8M in Q4 2021. 216 funds tracked by Wall St. Rank hold IMGN as of Q2 2022.

  • Lynx1 Capital Management reported no remaining Immunogen Inc position as of Q2 2022 after selling out during the quarter.
  • Lynx1 Capital Management sold 1,543,259 Immunogen Inc shares in Q2 2022, an estimated $7.35M.
  • Lynx1 Capital Management first reported a position in Immunogen Inc in Q4 2021 and held it in 2 quarters.
  • Lynx1 Capital Management's Immunogen Inc position peaked at $15.8M in Q4 2021.
  • 216 funds tracked by Wall St. Rank held Immunogen Inc as of Q2 2022.

Based on Lynx1 Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.